Evidence map›Paper›PMID 34807342›Full record

ArticleJournal of neuro-oncology2022

Stereotactic radiosurgery for melanoma brain metastases: dose-size response relationship in the era of immunotherapy.

Mehran Yusuf, Abbas Rattani, Jeremy Gaskins, Alexandria L Oliver, Steven F Mandish, Eric Burton, Michael E May, Brian Williams, Dale Ding, Mayur Sharma and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuro-oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Mehran Yusuf *Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
Abbas Rattani *Department of Radiation Oncology, School of Medicine, University of Louisville Hospital, 529 S. Jackson St, Louisville, KY, 40202, USA. abbas.rattani@louisville.edu.ORCID http://orcid.org/0000-0002-9562-526X
Jeremy GaskinsDepartment of Bioinformatics and Biostatistics, University of Louisville, Louisville, KY, USA.
Alexandria L OliverSchool of Medicine, University of Louisville, Louisville, KY, USA.
Steven F MandishDepartment of Radiation Oncology, School of Medicine, University of Louisville Hospital, 529 S. Jackson St, Louisville, KY, 40202, USA.
Eric BurtonNeuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Michael E MayDepartment of Radiation Oncology, School of Medicine, University of Louisville Hospital, 529 S. Jackson St, Louisville, KY, 40202, USA.
Brian WilliamsDepartment of Neurosurgery, University of Louisville Hospital, Louisville, KY, USA.
Dale DingDepartment of Neurosurgery, University of Louisville Hospital, Louisville, KY, USA.
Mayur SharmaDepartment of Neurosurgery, University of Louisville Hospital, Louisville, KY, USA.
Donald MillerDepartment of Medical Oncology, University of Louisville Hospital, Louisville, KY, USA.
Shiao WooDepartment of Radiation Oncology, School of Medicine, University of Louisville Hospital, 529 S. Jackson St, Louisville, KY, 40202, USA.
University of Louisville Hospital · USUniversity of Louisville · USNational Institutes of Health · USUniversity of Alabama at Birmingham · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PURPOSE/OBJECTIVE(S): To determine, for intact melanoma brain metastases (MBM) treated with single-fraction stereotactic radiosurgery (SRS), whether planning parameter peripheral dose per lesion diameter (PDLDm, Gy/mm) and lesion control (LC) differs with versus without immunotherapy (IO). MATERIALS/

methodsWe performed a retrospective analysis of patients with intact MBM treated with SRS from 2008 to 2019. Cox-frailty models were constructed to include confounders selected by penalized Cox regression models with a LASSO selector. Interaction effect testing was used to determine whether a significant effect between IO and PDLDm could be demonstrated with respect to LC.

resultsThe study cohort comprised 67 patients with 244 MBMs treated with SRS (30 patients with 122 lesions treated with both SRS and IO) were included. The logarithm of PDLDm was selected as a predictor of LC (HR 0.307, 95% CI 0.098-0.441), adjusting for IO receipt (HR 0.363, 95% CI 0.108-1.224). Interaction effect testing demonstrated a differential effect of PDLDm by IO receipt, with respect to LC (p = 0.048). Twelve-month LC rates for a 7.5 mm lesion receiving SRS (18 Gy) with IO versus without IO were 87.8% (95% CI 69.0-98.3%) versus 79.8% (95% CI 55.1-93.8%) respectively.

conclusionPDLDm predicted LC in patients with small MBMs treated with single-fraction SRS. We found a differential effect of dose per lesion size and LC by immunotherapy receipt. Future studies are needed to determine whether lower doses of single-fraction SRS afford similarly effective LC for patients with small MBMs receiving immunotherapy.

Indexed as

Brain NeoplasmsMelanomaRadioimmunotherapyRadiosurgeryDose-Response Relationship, RadiationHumansRetrospective StudiesBrain metastasisDoseImmunotherapyMelanomaSizeStereotactic radiosurgery

Identifiers

PMID34807342
PMCPMC8606626
OpenAlexW3215745566

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.